PIPELINE
LEADERSHIP
Management Team
Board of Directors
DISEASES
Acne vulgaris
Atopic dermatitis
Psoriasis
Vitiligo
NEWS & INVESTORS
CAREERS
COMPLIANCE PROGRAM
CONTACT
News & Investors
News & Investors
January 15, 2022
Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference
READ MORE
January 7, 2022
Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference
READ MORE
December 9, 2021
Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine
READ MORE
Recent Posts
Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference
Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference
Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine
The New England Journal of Medicine: Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Dermavant Showcases New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof in Patients with Plaque Psoriasis at the 30th EADV Virtual Congress
Archives
January 2022
December 2021
September 2021
August 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
November 2020
October 2020
August 2020
June 2020
May 2020
April 2020
January 2020
December 2019
June 2019
May 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
April 2018
September 2017
July 2017
December 2016
November 2015
Categories
Dermavant Sciences
News
RVT-201
RVT-501
RVT-502
RVT-504
Tapinarof
